Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for metastatic non-small cell lung cancer with PET-detected bone metastases
ACTRN12606000079549Phase 2Recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zoledronic acid in non-small cell lung cancer (NSCLC) and bone metastases, sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Visual metabolic response rate in asymptomatic non-osseous lesions. Started Feb 2006; status: recruiting.
02
Drugs
zoledronic acid
03
Conditions
non-small cell lung cancer (NSCLC)bone metastases
Beyond the preview
Go deeper on ACTRN12606000079549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000079549.